Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Targeted Anticancer Therapies Congress 2023

Seagen - ADCs’ journey into clinical use - Key considerations for improved outcomes

Leveraging immune stimulatory ADCs to target immune checkpoints

Date

07 Mar 2023

Session

Seagen - ADCs’ journey into clinical use - Key considerations for improved outcomes

Presenters

Elena Garralda Cabanas

Authors

E. Garralda Cabanas

Author affiliations

  • Early Drug Development Group, Vall d'Hebron University Hospital, 8035 - Barcelona/ES

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Introduction

Presenter: Solange Peters

Session: Seagen - ADCs’ journey into clinical use - Key considerations for improved outcomes

Resources:

Webcast

New ADC targets on the horizon

Presenter: Antoine Hollebecque

Session: Seagen - ADCs’ journey into clinical use - Key considerations for improved outcomes

Resources:

Webcast

Q&A and discussion

Presenter: Solange Peters

Session: Seagen - ADCs’ journey into clinical use - Key considerations for improved outcomes

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.